Peptide therapy and the FDA: what's actually legal in 2026

Peptide therapy is having a loud moment, and most of the noise is wrong. Vendors are shouting that "peptides are legal now" in 2026 — that is not what the record says. Here is the honest, source-based version: BPC-157 and MOTS-C have no FDA-approved labeling^[1], the peptides everyone is arguing about sit in a gray area the FDA has not resolved, and the widely covered July meeting is a review, not a clearance. We don't sell these peptides today — and if any of them clears the FDA's review to become a legitimate option, this is the page that will say so. We're writing this because the truth is a better guide than the hype.

Are peptides FDA-approved?

Almost none of the popular ones are. BPC-157, CJC-1295 and ipamorelin have no FDA-approved labeling^[2] — the openFDA drug label index returns no approved labeling for them under generic name, brand name or substance name. MOTS-C, Semax and Epitalon have no FDA-approved labeling^[3] either. TB-500 is sold as a fragment of thymosin beta-4. A search of the FDA label index for thymosin returns no approved labeling. "Peptide therapy" is a marketing umbrella, not an approval status.

Sermorelin is the partial exception, and the reason is worth understanding. Sermorelin was marketed in the United States under the brand name Geref, and in 2008 its manufacturer discontinued production for commercial reasons rather than for safety. Sermorelin has no current FDA-approved labeling^[7]. Individual results vary.

Is BPC-157 legal in 2026?

Two facts, stated precisely. BPC-157 has no FDA-approved labeling, and BPC-157 does not appear on the 503A bulks list at 21 CFR 216.23(a)^[8] — a list that currently names just six bulk drug substances, none of them peptides.

Now read the next part carefully, because this is where both the vendors and the scare stories overreach. Absence from 216.23(a) does not by itself mean a substance cannot be compounded. Section 503A permits a bulk drug substance to be used in compounding if any one of three independent conditions is met: it is the subject of a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on the 216.23(a) list. Testosterone, for example, is absent from 216.23(a) and can still be compounded, because it is a component of FDA-approved drugs^[11].

Anyone collapsing those two facts into "cleared to buy" — or into a flat legal verdict — is selling you something. Products sold online as "research chemicals" or "not for human use" are exactly what those labels say.

What is the FDA actually doing about peptides in 2026?

On April 15, 2026, the FDA gave notice that it would remove 12 peptide bulk drug substances from Category 2 of its 503A bulk drug substances list, effective roughly a week later. The nominations behind those substances had been withdrawn by the nominators, and that withdrawal is what triggered the removal.

The FDA simultaneously published a Federal Register notice announcing that it will convene the Pharmacy Compounding Advisory Committee (PCAC) at public meetings on July 23–24, 2026, and again before the end of February 2027, to discuss whether these peptides should be added to the 503A bulks list — the step that would formally authorize their use in compounding.

Here is the part the marketing emails skip. Removal from Category 2 does not, by itself, place these substances on the 503A bulks list or into Category 1. They sit in a gray area until the PCAC meets and the FDA takes final action. A meeting on the calendar is not an approval on the books: it is a review, and a review is not a clearance. Two details sharpen the point. First, when peptides were withdrawn from Category 2 and brought before the PCAC before, the committee recommended against adding them to the bulks list in each case. Second, the PCAC's recommendations are advisory only — the FDA retains authority to accept, modify or reject them.

The push does have political wind behind it. HHS Secretary Robert F. Kennedy Jr. signaled on The Joe Rogan Experience on February 27, 2026 that the administration expected to make roughly 14 peptides more accessible through lawful channels. That is a real signal about direction. It is not a change in what is legal today.

One structural rule cuts through much of the remaining confusion: a peptide longer than 40 amino acids is treated as a biologic rather than a drug, and biologics fall outside the 503A regulatory pathway entirely. That single line disqualifies a large share of what gets marketed as "peptide therapy."

Can a medical provider prescribe peptides?

Sometimes — and only where it is clinically appropriate and legally permitted. Sermorelin is the clearest example: it may be prescribed off-label and prepared by a state-licensed compounding pharmacy where a medical provider judges that appropriate. For the peptides still outside that pathway, a responsible medical provider will not prescribe them regardless of what a website promises. Prescriptions are issued at the sole discretion of a licensed provider, and only where clinically appropriate.

For men chasing energy, drive and body-composition goals, the honest move is to start with a diagnosis, not a peptide. Low testosterone is a diagnosable condition, confirmed with symptoms and morning bloodwork^[20], and it has established treatments — see testosterone replacement therapy and how our care works. If fertility preservation matters, enclomiphene is another provider-directed option. These are real, established therapies — not gray-market chemistry.

Are compounded peptides safe?

"Compounded" is not a synonym for "proven safe." Compounded medications are not FDA-approved. They are prepared in FDA-regulated facilities.

Category 2 was never a paperwork bucket. It is the category the FDA reserves for substances it has determined raise significant safety risks^[22], and that designation had been the basis for FDA enforcement action against compounders distributing these peptides^[23]. Those peptides did not leave Category 2 because the safety questions were answered. They left because the nominations were withdrawn — a procedural event, not a safety finding.

The gray market is a separate problem, and the bluntest warning on record comes from the official pushing hardest for access. Secretary Kennedy described the gray-market peptide trade as "very, very substandard" and warned that consumers buying there "have no idea" whether they are getting a legitimate product^[24]. Lawful compounding, by contrast, requires pharmaceutical-grade active ingredient from an FDA-registered manufacturer, accompanied by a valid certificate of analysis. A vial from a website carries no such assurance.

Peptide therapy for men: separating the search from the science

Search demand for "peptide therapy for men" and "fda peptides 2026" is real, and it is driven by legitimate frustration — fatigue, slow recovery, stalled progress in the gym. That frustration deserves a real answer, not a vial of something the FDA won't stand behind. When a company tells you a peptide is "legal now," ask them to show you the approval. In 2026, they can't.

What you can do is get properly worked up by a licensed medical provider, confirm what's actually going on with bloodwork, and pursue treatments that have a real regulatory footing. That's the whole idea behind how we're set up: intake, labs, provider review, and a prescription only if it's clinically appropriate. No hype, no "research chemicals," no promises.

FAQ

Is BPC-157 FDA-approved?

No. BPC-157 has no FDA-approved labeling, and it does not appear on the 503A bulks list at 21 CFR 216.23(a). Those are the two facts that matter; everything past them is marketing.

Are CJC-1295 and ipamorelin legal to prescribe?

CJC-1295 and ipamorelin have no FDA-approved labeling, and neither appears on the 503A bulks list at 21 CFR 216.23(a). A responsible medical provider will not prescribe them on the strength of online marketing claims.

Does the July 2026 FDA review mean peptides are being approved?

No. The July 23–24, 2026 PCAC meeting is a review of whether certain peptides should be added to the 503A bulks list — not an approval or a clearance. The committee's recommendation is advisory, and the FDA can accept, modify or reject it.

Why is sermorelin treated differently?

Sermorelin was marketed in the United States as Geref until its manufacturer discontinued production in 2008 for commercial reasons. It may still be prescribed off-label and prepared by a state-licensed compounding pharmacy where clinically appropriate. It is the notable exception, not the rule. Individual results vary.

What does the "40 amino acids" rule mean?

A peptide longer than 40 amino acids is treated as a biologic rather than a drug, and biologics fall outside the 503A regulatory pathway entirely. That rule alone disqualifies many products marketed as peptide therapy.

Do you sell or prescribe peptides?

Not the unapproved ones. We don't sell peptides that haven't cleared the FDA — and if that changes, you'll find it here first. For men looking for legitimate help with low testosterone, a licensed medical provider can evaluate established options through our intake platform.